Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomics for optimization of chemotherapy in colorectal carcinoma
2010-019805-41Phase 4Active
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jun 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of irinotecan, oxaliplatin, fluorouracil, capecitabine, bevacizumab and 2 more in colorectal cancer (CRC), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Identification of predictive biomarkers for therapy responsiveness. Started Jun 2010; status: active.
02
Drugs
irinotecanoxaliplatinfluorouracilcapecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-019805-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019805-41.